DHR · Full Picture

DANAHER CORP /DE/ — the full picture

Earnings window · 2026-06-30 to 2026-09-24 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Revenue Performance and Mix · Revenue growth & mixPriority 80
    -0.4% revenue; 3 sources (news, press_release, sec_filing); 4 forward row(s); structured_verified
    Since joining Danaher in 2017, Julie Sawyer Montgomery has helped grow the Diagnostics business from approximately $6.0 billion in revenue in 2017 to approximately $11.0 billion today.
  2. Interest Expense Trends · Operating expenses (SG&A)Priority 75
    -36.2% operating_income; 2 sources (press_release, sec_filing); 6 forward row(s); structured_verified
    The Company estimated amortization of acquisition-related intangible assets of $0.5 billion for the third quarter and $1.9 billion for the year ending December 31, 2026.
  3. Masimo Acquisition · M&A and divestituresPriority 74
    -10.7% cash (realized); 2 sources (news, sec_filing); 4 forward row(s); structured_verified
    On June 10, 2026, the Company acquired Masimo by acquiring all of the outstanding shares of Masimo’s common stock for a cash purchase price of approximately $9.8 billion, or $180.00 per share, net of cash acquired.
  4. Biotechnology Demand Trends · Demand, orders & backlogPriority 64
    +6.8% revenue (realized); 3 sources (news, press_release, sec_filing); 1 forward row(s); quote_verified
    A market report forecasts the global research use recombinant protein market to grow from $1.11B in 2026 to $1.55B by 2031 and profiles Danaher as a key player.
  5. Guidance / Outlook · Guidance & outlookPriority 63
    +3.0% revenue; 3 sources (news, press_release, sec_filing); 8 forward row(s); quote_verified
    Quiver Quantitative reported that Danaher maintained guidance after a CEO transition.
  6. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 55
    +2.0% revenue; 2 sources (news, press_release); 6 forward row(s); quote_verified
    DANAHER CORP /DE/ completed the acquisition of Masimo for $9.9 billion (characterized as 'its $9.9 billion Masimo acquisition' in reporting).
  7. Outstanding Indebtedness · Debt, leverage & refinancingPriority 54
    -4.0% liability (realized); structured_verified
    The Company financed the Masimo Acquisition using cash on hand and proceeds from the issuance of long-term debt and commercial paper.
  8. Competition and Market Position · Competition & market sharePriority 52
    quote_verified
    Under Julie Sawyer Montgomery's leadership, the Diagnostics platform has consistently gained share in attractive end markets.
  9. Liquidity and Cash Position · Liquidity & cash positionPriority 52
    -3.4% cash (realized); 1 forward row(s); structured_verified
    Total cash provided by (used in) financing activities was $7,319 million for the six-month period ended June 26, 2026 and $(1,502) million for the six-month period ended June 27, 2025.
  10. Operating Income and Margins · Operating income & profitabilityPriority 50
    +5.2% net_income (realized); 1 forward row(s); quote_verified
    Adjusted operating profit margin (non-GAAP) for the three-month period ending September 25, 2026 is approximately 26.5%.
  11. Income Tax Rate Changes · TaxPriority 49
    2 sources (press_release, sec_filing); 1 forward row(s); quote_verified
    The Company projected an effective tax rate of approximately 17.0% for the three-month period ending September 25, 2026 and for the year ending December 31, 2026.
  12. Gross Margin Drivers · Gross marginPriority 47
    2 sources (news, sec_filing); quote_verified
    Gross profit for the three-month period ended June 26, 2026 was $3,611 million and cost of sales was $2,654 million, yielding a gross profit margin of 57.6%.

Threads by pillar

Revenue & Demand Priority 85 · 5 threads

Costs & Margins Priority 84 · 5 threads

Capital & Balance Sheet Priority 79 · 8 threads

Strategy & Portfolio Priority 77 · 2 threads

Legal, Regulatory & Policy Priority 42 · 3 threads

Guidance & Outlook Priority 63 · 1 thread

Macro & Market Conditions Priority 63 · 3 threads

Management & Governance Priority 37 · 1 thread

Unclassified Priority 52 · 3 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-36.2%+36.2%+3.3%
revenue+3.8%+7.1%+25.2%
net_income-3.0%+3.8%+2.0%
margin——+10.6%
cash——-16.0%
liability——-4.0%
assets——+5.4%